SAN DIEGO, Sept. 12, 2017 -- The Shareholders Foundation, Inc. announces that a deadline is coming up on September 25, 2017 in the lawsuit that was filed for certain investors in Zebra Technologies Corp. (NASDAQ:ZBRA) shares over alleged Securities Laws Violations by Zebra Technologies Corp.
Investors who purchased shares of Zebra Technologies Corp. (NASDAQ:ZBRA) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
On July 26, 2017, a lawsuit was filed against Zebra Technologies Corp. over alleged violations of securities laws. The plaintiff claims that the defendants failed to disclose that Zebra Technologies had understated its income taxes through the end of 2015, underaccrued certain 2015 estimates, in particular with respect to its sales commission plan, and overstated the net realizable value of trade receivables acquired in connection with the Company’s acquisition of Motorola’s Enterprise division.
The plaintiff further alleges that Zebra Technologies Corp. also failed to disclose the impact of material weaknesses identified in its internal controls and procedures over financial reporting and disclosure, which caused the misstatements and rendered the Company’s financial guidance for 2015 and the first and second quarters of 2016 materially false and misleading.
Those who purchased Zebra Technologies Corp. (NASDAQ:ZBRA) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108


JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



